← Immuron Ltd (IMRN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Immuron Ltd (IMRN)
Pharmaceutical Preparations · market cap $10M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Immuron Ltd (IMRN) is a small-cap Australian pharmaceutical company with 7 employees and a ~$248M market cap trading around $1.26. Its lead asset IMM-124E is in Phase 2 for NASH, with a second pipeline asset (Travelan) in Phase 2 for diarrhea. Financial details including cash position, runway, and dilution history are not disclosed in available data.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| IMM-124E | Phase 2 | Non-alcoholic Steatohepatitis (NASH) |
| Travelan | Phase 2 | Diarrhea |
| IMM 124-E (Hyperimmune Bovine Colostrum) | Phase 2 | Hepatitis, Alcoholic |
Price & technical context
3-month
+6.4%
6-month
+49.7%
12-month
-39.6%
52-wk range
$0.70–$2.35
vs 50-day MA
-3.1%
vs 200-day MA
+15.5%
Realized vol
101.9%
Max drawdown
-75.0%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for IMRN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.